

(19) **DANMARK**

(10) **DK/EP 3439707 T3**



(12) **Oversættelse af
europæisk patentskrift**

Patent- og
Varemærkestyrelsen

-
- (51) Int.Cl.: **A 61 L 27/22 (2006.01)** **A 61 L 27/38 (2006.01)** **A 61 L 27/50 (2006.01)**
A 61 L 27/52 (2006.01) **A 61 L 27/60 (2006.01)** **A 61 L 31/00 (2006.01)**
A 61 L 31/04 (2006.01) **A 61 L 31/14 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2022-08-29**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2022-06-08**
- (86) Europæisk ansøgning nr.: **17718281.3**
- (86) Europæisk indleveringsdag: **2017-04-05**
- (87) Den europæiske ansøgnings publiceringsdag: **2019-02-13**
- (86) International ansøgning nr.: **US2017026204**
- (87) Internationalt publikationsnr.: **WO2017176919**
- (30) Prioritet: **2016-04-05 US 201662318389 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Regents of the University of Minnesota, 600 McNamara Alumni Center , 200 Oak Street SE, Minneapolis, MN 55455-2020, USA**
- (72) Opfinder: **TRANQUILLO, Robert, 1267 Wyncrest Court, Arden Hills, MN 55112, USA**
SYEDAIN, Zeeshan, 2900 4th St., S.E., Apt. 240, Minneapolis, MN 55414-4450, USA
- (74) Fuldmægtig i Danmark: **CHAS. HUDE A/S, Langebrogade 1, 2. B2, 1411 København K, Danmark**
- (54) Benævnelse: **MODIFICEREDE VÆV MED STRUKTURELLE KOMPONENTER INDBYGGET DERI OG FREMGANGSMÅDER TIL FREMSTILLING OG ANVENDELSE**
- (56) Fremdragne publikationer:
WO-A1-02/090528
WO-A1-2010/028197
WO-A1-2012/111000
WO-A2-2004/038004
US-A1- 2014 180 399

DESCRIPTION

TECHNICAL FIELD

[0001] This disclosure generally relates to engineered tissues having structural components embedded therein, and methods of making and using such engineered tissues having structural components embedded therein.

BACKGROUND

[0002] Suturing tissue to a stent is required for essentially all transcatheter heart valve replacements, yet suturing tissue to a stent is an incredibly tedious, manual, and time-consuming process. For example, suturing tissue to a stent can require up to one week for one professional sewer to create one valve from the industry-standard processed animal tissue, which typically is bovine pericardium. Similar processes also are required to produce replacement venous valves as well as certain vascular grafts.

[0003] In addition to significantly reducing or eliminating the time-consuming process of suturing tissue to a stent, the present disclosure provides for structural reinforcement of the engineered tissue.

[0004] US 2014/180399 describes a heart valve comprising heart valve leaflets. Said leaflets comprise a mesh material, preferably from nitinol. A bioactive material is used to coat the valve. This bioactive material may be a fibrin gel in combination with cells and growth factors. The construct is cultured to grow a cell layer on it.

SUMMARY

[0005] The present invention is defined by the independent claims, while the dependent claims concern the preferred embodiments. Any "embodiment" or "example" which is disclosed in the description but is not covered by the claims should be considered as presented for illustrative purpose only. This disclosure provides engineered decellularized tissues having structural components embedded therein. This disclosure also provides methods of making and methods of using engineered tissues having structural components embedded therein.

[0006] In one aspect, a method of making an engineered decellularized tissue that includes a structural component embedded therein is provided, wherein a portion of the structural component is embedded in the engineered decellularized tissue, and a portion of the structural component is not embedded in said engineered decellularized tissue.

[0007] Such a method generally includes combining fibrinogen, thrombin, and matrix-producing cells (e.g., fibroblasts, smooth muscle cells and/or interstitial cells) to produce a cell-seeded hydrogel; forming the cell-seeded hydrogel on, in, around, and/or within a structural component. In some embodiments, the method further includes manipulating, mechanically, the tube in the presence of culture medium to produce an engineered tissue. According to the claimed invention, the method further includes decellularizing the biologically-engineered tubular graft. In some embodiments, the method further includes recellularizing or chemically modifying the engineered tissue.

[0008] In another aspect, an engineered decellularized tissue is provided that includes a portion of a structural component embedded therein, wherein a portion of the structural component is not embedded in the engineered decellularized tissue. According to the claimed invention, the structural component is thus partially embedded in the engineered tissue. Representative structural components include, without limitation, a stent, a tab, mesh, or a sheath. In some embodiments, the engineered decellularized tissue is a vascular graft, a heart valve, a vein valve, an arterio-venous graft, an ureter, an urethra, an esophagus a trachea, skin, tendons and ligaments, uterine (e.g., fallopian) tubes, or hernia mesh.

[0009] In still another aspect, a composition is provided that includes a structural component embedded within a decellularized engineered tissue. According to the claimed invention, the structural component of such a composition typically includes a first end and a second end, where the first end includes a valve stent and the second end includes a tubular structure. Generally, the tubular structure of the structural component is embedded in the engineered decellularized tissue, whereas the valve stent is not embedded within said engineered decellularized tissue.

[0010] In some embodiments, the tubular structure of the structural component includes a valve leaflet wire. In some embodiments, the composition includes a sewing cuff attached to the second end of the structural component. In some embodiments, the structural component is made from nitinol.

[0011] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods and compositions of matter belong. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the methods and compositions of matter, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

DESCRIPTION OF DRAWINGS

[0012]

Figure 1 is a photograph showing one embodiment of an engineered tissue with an embedded

wire mesh structure.

Figure 2 is a photograph showing one embodiment of an engineered tissue with two embedded structural components. The arrow on the left shows an embodiment of an engineered tissue with an embedded stent, and the arrow on the right shows an embodiment of an engineered tissue with an embedded wire mesh structure.

Figure 3 is a photograph showing one embodiment of an engineered tissue with an embedded tab.

Figure 4A is an image of an engineered tissue stained with trichrome to show the collagen matrix encapsulating the mesh structure. The hole in the center was the portion of the structure that was removed for cryosectioning.

Figure 4B is a photograph of engineered tissue (white color) with embedded mesh structure (dark).

Figure 5A is a schematic of a wire mesh structural component embedded in an engineered tissue shaped in the form of a tube.

Figure 5B is a schematic of a wire mesh structural component embedded in an engineered tissue shaped in the form of a tube, where one end of the engineered tissue has been anchored to form an engineered valve.

Figure 6A shows an image of a nitinol wire and nitinol stent embedded into engineered tissue.

Figure 6B is an image that shows that, after folding the engineered tissue structure with nitinol wire into the stent, a tri-leaflet aortic valve with an inner diameter of 24 mm is formed. The image of the valve after sewing the folded structure is shown on the right.

Figure 6C is an image of an end on view of the valve from Figure 6B being crimped to a diameter of 8 mm (from an initial diameter of 24 mm).

Figure 6D are images showing tissue material before (left) and after (right) crimping, showing no qualitative tear, cut or peeling of tissue from the embedded structure.

Figure 7A is an image showing a side view of a mold having a tubular cavity for placing the nitinol stent and channels cut into the mold for leaflets.

Figure 7B is an image of a side view of a stent embedded into engineered tissue.

Figure 7C is an image of a top-down view showing two leaflets within the embedded stent.

Figure 7D is an image of an end-on view of leaflets in closed (left) and open (right) positions within the embedded stent.

Figure 8A is a graph showing a back-pressure failure test of the bi-leaflet tissue-engineered vein valve (shown in Figure 7) compared to a native ovine vein valve.

Figure 8B is a graph showing the results of a dynamic flow test of the bi-leaflet tissue-engineered vein valve (shown in Figure 7) compared to a native ovine vein valve.

DETAILED DESCRIPTION

[0013] Provided herein is an engineered decellularized tissue that has one or more structural components embedded within the engineered tissue. The process is based on forming a hydrogel containing cells onto, into, around and/or within one or more structural components. Under suitable culture conditions and in the presence of, for example, thrombin, the cells remodel the hydrogel into tissue, which forms on, in around and/or within the structural component(s), thereby embedding the structural component(s) in the engineered tissue. The manner of embedding the structural component within the engineered tissue and the manner in which the engineered tissue is obtained (e.g., by remodeling of a cell-seeded hydrogel) results in a number of unique features. According to the claimed invention, the structural component is partially lodged or embedded in or within the engineered tissue. If desired, the result can be a structural component or portion thereof that is integrated or entwined in the engineered tissue or a portion thereof.

Engineered Tissues

[0014] The use of hydrogels in tissue engineering is known. See, for example, U.S. Patent No. 6,666,886 and U.S. Publication No. 2014/0058496). Typically, fibrinogen (or a suitable alternative such as a modified fibrinogen), thrombin, and cells capable of producing tissue matrices (e.g., fibroblasts, smooth muscle cells, interstitial cells) are combined in a hydrogel solution, and the resulting cell-seeded hydrogel is molded (or cast, shaped, deposited, formed, or printed) into the desired shape and to appropriately accommodate and embed the structural component therein. The shape of the structural component will determine the extent to which the cell-seeded hydrogel can be molded (or cast, shaped, deposited, formed, or printed) on, in, around and/or within the structural component. Under appropriate culture conditions, the cell-seeded hydrogel is remodeled into an extracellular matrix by the cells, which maintains the original shape and results in the one or more structural components being embedding into the engineered tissue. Based on the manner in which the engineered tissue is produced, the resulting engineered tissue, when examined in a cross-section, is uniform and lacks any layers.

[0015] Hydrogel solutions generally refer to aqueous solutions containing hydrophilic polymeric chains that can include natural or synthetic polymers. Representative hydrogels include, for example, agarose, methylcellulose, hyaluronan, and combinations thereof. The amount of hydrogel used in a composition described herein can range from about 1% to about 80% (e.g., about 2% to about 75%, about 5% to about 75%, 20% to about 70%, about 30% to about 60%, about 40% to about 50%, or about 50%). The presence of and the actual amount of one or

more hydrogels will depend upon the desired features of the cell-seeded hydrogel or the subsequently produced biologically-engineered tubular graft (e.g., softness or hardness, flexibility, absorbency).

[0016] The cells used herein (i.e., in the cell-seeded hydrogel) are those cells that are able to convert fibrinogen, in the presence of thrombin, into extracellular matrix. Fibroblasts are capable of forming tissue matrices and can be used in a hydrogel as described herein, as can any number of cells that are capable of producing tissue matrices or assist in the production of tissue matrices (e.g., smooth muscle cells, interstitial cells). The cells used to seed a hydrogel can be a single cell type (e.g., fibroblasts or smooth muscle cells or interstitial cells) or the cells used to seed a hydrogel can be a multitude of cell types (e.g., fibroblasts and smooth muscle cells, or fibroblasts and interstitial cells, or smooth muscle cells and interstitial cells). Further, the cells can be from any number of organisms (e.g., human, primate, rodent) and any number of tissues (e.g., dermis, lung, connective tissue, kidney). It would be appreciated that the cells can be added to the hydrogel prior to the gel being appropriately shaped or after the gel has been appropriately shaped on, in, around and/or within the structural component.

[0017] The size and shape of an engineered tissue as described herein will depend entirely on its intended use and/or the intended use of the structural component. As shown herein, an engineered tissue can have a tubular shape having a desired length and diameter(s), but an engineered tissue also can be flat or curved as needed. Typically, an engineered tissue as described herein includes a first end and a second end, and, when molded (or cast, shaped, deposited, formed, or printed) in a tubular shape, an exterior and interior (or annular) surface, which defines a longitudinal axis.

[0018] During remodeling of the cell-seeded hydrogel into an extracellular matrix and, ultimately, the engineered tissue, the hydrogel and/or the extracellular matrix can be mechanically manipulated (or "conditioned") in any number of fashions, including, without limitation, mechanical manipulation (e.g., static culture, circumferential stretching, longitudinal stretching, inflation / distention), electrical stimulation (e.g., field stimulation, AC or DC current), and/or biological manipulation with molecules / compounds such as growth factors and cytokines. Usually, manipulation of the gel / matrix is cyclic or periodic.

[0019] According to the claimed invention, once remodeling is complete or near complete, the engineered tissue is decellularized (e.g., to remove the matrix-forming cells). Decellularization is known in the art and can be performed using a number of different methods. See, for example, WO 2007/025233, WO 2010/120539, Ott et al. (2008, Nat. Med., 14:213-21), Baptista et al. (2009, Conf. Proc. IEEE Eng. Med. Biol. Soc., 2009:6526-9) or Crapo et al. (2011, Biomaterials, 32:3233-43). The engineered decellularized tissue can be recellularized with one or more desired cell types. The type(s) of cells used for recellularization will depend on its intended use. Cells used in the recellularization process can be stem cells (e.g., embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), or adult-derived stem cells), or cells used in the recellularization process can be non-stem cells (e.g., one or more types of cells at some stage of differentiation). Simply by way of

example, non-stem cells include, without limitation, endothelial cells, epithelial cells, fibroblasts, smooth muscle cells, and/or any tissue- or organ-specific cells (e.g., liver, heart, lung, bone, kidney, pancreas). In some instances, the engineered decellularized tissues can be implanted and recellularized naturally *in vivo*.

[0020] Alternatively or additionally, the engineered tissue (i.e. decellularized engineered tissue) can be chemically or physically modified. Chemical modifications to engineered tissue include, for example, matrix crosslinking by chemical agents (e.g., glutaraldehyde) or enzymes (e.g., transglutaminase), or conjugation of proteins (e.g., heparin) or peptides by enzymes or via high affinity domains of fusion proteins. Physical modifications (e.g. for matrix crosslinking) include, without limitation, dehydration, heating, and/or UV irradiation.

[0021] Engineered tissues made using hydrogels and the appropriate cells possess a number of beneficial features, such as, without limitation, circumferential alignment of fibers (for tubular structures, which results in a greater tensile stiffness in the circumferential direction than in the longitudinal direction) and a high burst pressure (e.g., at least 3500 mm Hg, at least 4000 mm Hg, or greater than 4000 mm Hg, without bursting).

Structural Components

[0022] A structural component as described herein can take essentially any shape desired. As shown herein in various embodiments, structural components can be a mesh structure (see Figure 1), a stent (see the right portion of Figure 2, Figure 6A, Figure 7B, and Figure 7C), a tab (see Figure 3), or a leaflet wire (see the left portion of Figure 2, Figure 6A, and Figure 6B). Although not part of the claimed invention, the addition of a structural component that is wholly embedded within the engineered tissue (see, for example, Figure 7C) can enable easy suturing to another object (e.g. a stent), or to a sheath, and increase the strength and integrity of the overall resulting product.

[0023] Structural components that are suitable for use herein can be made from materials that are known in the art. Essentially any material can be used that does not cause an immune response in the subject. For example, any of the materials that are used to make stents can be used in a structural component as described herein. Such materials include, without limitation, metals or alloys (e.g., shape memory alloys such as, e.g., nitinol), plastics, ceramics, fabrics, and combinations thereof.

[0024] A structural component as described herein can include a first end and a second end, and, when the structural component includes a tubular shape, an exterior and interior, or annular, region, which defines a longitudinal axis. In some instances, the first end of the structural component can be embedded within the first end of an engineered tissue; in some instances, a first structural component can be embedded within the first end of an engineered tissue and a second structural component can be embedded within the second end of the engineered tissue. In some instances not according to the claimed invention, the entirety of a

structural component can be embedded within the engineered tissue (see, for example, Figures 1, 7B and 7C), while in some instances which are according to the claimed invention, only a portion of the structural component is embedded within the engineered tissue (see, for example, Figures 2 and 6A).

[0025] As described herein, an engineered tissue can contain one or more structural components embedded therein. See, for example, Figure 2, which shows a stent embedded on the left end and a mesh structure embedded on the right end. Also as described herein, the structural component(s) can provide one or more than one functionality. For example, Figure 2 shows an engineered tissue in which the embedded structural components function as a stent and as a means to attach the engineered tissue to existing tissue. It is noted that, while the stent and the wire mesh shown in Figure 2 are separate structural components, both functionalities could be engineered into a single structural component.

Methods of Using

[0026] A decellularized engineered tissue having a structural component partially embedded therein can be implanted into a subject.

[0027] Similarly, a decellularized engineered tissue having a structural component partially embedded therein can be recellularized, and the resulting recellularized engineered tissue having a structural component partially embedded therein can be implanted into a subject.

[0028] When the shape of the engineered tissue having a structural component embedded therein includes a tubular shape, the engineered tissues having a structural component embedded therein as described herein can be used to replace any part of the vasculature (e.g., a tissue-engineered vascular graft, a tissue-engineered heart valve, a tissue-engineered vein valve, a tissue-engineered arterio-venous graft) or other tubular structures (e.g., a tissue-engineered ureter, a tissue-engineered urethra, a tissue-engineered uterine (e.g., fallopian) tube), a tissue-engineered esophagus, a tissue-engineered trachea). Neither the engineered tissue nor the structural component that is embedded therein, however, is limited to a tubular shape, and, thus, can be used for virtually any application that involves a biological tissue (e.g., tissue-engineered tendons and ligaments, tissue-engineered skin, tissue-engineered hernia mesh (for repair)).

[0029] In some instances, when the shape of the engineered tissue having a structural component embedded therein includes a tubular shape, an engineered valve can be created by anchoring the tissue at one end of the engineered tissue portion at two points (for a bi-leaflet valve), three points (for a tri-leaflet valve) or four points (for a quad-leaflet valve). Anchoring can be achieved using, for example, one or more sutures through or around the embedded component to attach the tissue to a surrounding stent. See, for example, Figure 6B.

[0030] In accordance with the present invention, there may be employed conventional

molecular biology, microbiology, biochemical, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. The invention will be further described in the following examples. These examples are to be considered as reference-examples which are included for illustrative purposes only, as they do not disclose an engineered decellularized tissue comprising a structural component which is only partially embedded therein.

REFERENCE-EXAMPLES

Example 1-Engineered Tissue Having a Structural Mesh Embedded Therein

[0031] Figure 1 shows one embodiment of an engineered tissue having an embedded mesh component. The embodiment shown in Figure 1 used an aluminum mesh (McMaster Carr), which was rolled into a tube and the two long ends were tied using silk sutures (Fine Science Tools) to form a tubular structure having a diameter of 6 mm. The aluminum tubular structure was then inserted around a glass rod (McMaster Carr) having a diameter of 4 mm, leaving a cavity of 1 mm around the circumference. This was then inserted into a glass shell having an inner diameter of 8 mm (McMaster Carr). A fibrinogen-based mixture comprising 4 mg/ml fibrinogen (Sigma), 1 million cells neonatal dermal fibroblasts (Lonza), and 0.8 units/ml of thrombin (Sigma) was injected into the cavity formed by the glass rod and shell and having the aluminum mesh suspended in between. Once the fibrinogen formed a fibrin gel due to the enzymatic action of thrombin, the outer glass shell and inner glass tube was removed, leaving behind an aluminum tubular mesh embedded within a formed fibrin gel.

[0032] The structure was then cultured in a polycarbonate jar (Nalgene) filled with 50 ml of DMEM media (Gibco) with 10% Fetal Bovine Serum (HyClone) supplemented with insulin (Sigma) and ascorbic acid (Sigma). The image shows the resulting structure on day 3. The structure was cultured for additional 18 days for a total of 21 days of culture in media. The sample was then cut open with scissors and the image was taken to demonstrate that the aluminum structure was embedded within the engineered tissue (Figure 4B). The aluminum was removed and tissue was fixed in 4% paraformaldehyde. The fixed tissue was cryosectioned and stained with trichrome stain (leaving behind the hole visible in Figure 4A). The fibroblast cell nuclei are stained black and the cell-produced collagen is stained green. The original fibrin, which would have stained red, is not visible, indicating that the original fibrin gel was completely degraded by the cells as they formed the collagenous tissue.

Example 2-Engineered Tissue Having a Nitinol Wireform and Nitinol Stent Embedded Therein

[0033] Figure 2 shows one embodiment of an engineered tissue with an embedded Nitinol

wireform and Nitinol stent. The embodiment shown in Figure 2 used a Nitinol wireform having a diameter of 0.254 mm (0.01 inch), which was formed into a crown shape with three peaks and three valleys having an inner diameter of 24 mm, and then heat set at 54°C for 40 minutes to shape set the nitinol. In addition, a Nitinol stent was formed by expanding a Nitinol tube and laser cutting holes to form a mesh with diamond shaped holes and having an inner diameter of 24 mm. The two Nitinol structures were sleeved over a glass rod (McMaster Carr) having a diameter of 22 mm. The glass rod and Nitinol structures were placed into a polycarbonate tube having an inner diameter of 28 mm (McMaster Car). A cell suspension comprising 4 mg/ml fibrinogen (Sigma), 1 million cell dermal fibroblast (Coreal), and 0.8 Units/ml thrombin (Sigma) was then injected into the cavity formed by the glass rod and shell and having the Nitinol wireform and stent suspended in between. Once the fibrinogen formed fibrin gel due to the enzymatic action of thrombin, the outer polycarbonate shell was removed, leaving behind the Nitinol structures embedded within a fibrin gel tube formed around the inner glass rod. This was placed in a polycarbonate jar (Nelgene) filled with 250 ml of DMEM media (Gibco) with 10% Fetal Bovine Serum (HyClone) supplemented with insulin (Sigma) and ascorbic acid (Sigma). The image shows the structure on day 7 after manufacturing. The structure was cultured for an additional 28 days for a total of 35 days.

Example 3-Engineered Tissue Having a Nylon Tab Embedded Therein

[0034] Figure 3 shows one embodiment of an engineered tissue with an embedded nylon tab. The embodiment shown in Figure 3 used a laser cut nylon tab having an oval shape and three holes drilled into the central region of the tab. Overall, the tab was 3 mm in length and 1.5 mm in width. Each of the three holes had a diameter of 0.4 mm. Three tabs were suspended into a cavity formed by an inner glass rod (McMaster Carr) having a diameter of 24 mm and an outer polycarbonate shell (McMaster Car) having an inner diameter of 28 mm. A fibrinogen-based mixture comprising 4 mg/ml fibrinogen (Sigma), 1 million cells of dermal fibroblasts (Coreal) and 0.8 Units/ml thrombin (Sigma) was then injected into the cavity formed by the glass rod and shell and having the tabs suspended in between. Once the fibrinogen was formed into a fibrin gel in the presence of the thrombin catalyst, the outer polycarbonate shell was removed, leaving behind the nylon tabs embedded within a formed fibrin gel. The inner glass rod was kept for structures stability and the entire structure was placed in a polycarbonate jar (Nelgene) filled with 250 ml of DMEM media (Gibco) with 10% Fetal Bovine Serum (HyClone) supplemented with insulin (Sigma) and ascorbic acid (Sigma). The image shows the structure on day 7 after manufacturing. The structure was cultured for an additional 28 days for a total of 35 days of culture in media.

Example 4-Engineered Tissue Having a Valve Stent and Wire Form Embedded Therein

[0035] A nitinol valve stent and wire form was embedded in engineered tissue by placing a laser cut nitinol stent and a heat-formed nitinol wire in a tubular mold (Figure 6A). The mold

was filled with a hydrogel solution containing fibrinogen, thrombin and dermal fibroblasts.

[0036] Once the gel was formed, the embedded nitinol structure was removed from the mold and cultured in cell culture media for 7 weeks.

[0037] The final product was a cell produced extracellular matrix containing a nitinol structure embedded therein as shown in Figure 6B. The valve was formed by inverting the wire form inside the lumen of the embedded nitinol frame (Figure 6C). To evaluate the integration between the nitinol stent and the surrounding cell-produced extracellular matrix, the stent was crimped from a diameter of about 24 mm to a diameter of about 8 mm (Figure 6D). After being crimped for 15 minutes, the stent was removed and the structure was evaluated for qualitative damage. No tissue tearing, peeling or cuts were seen following crimping of the nitinol stent embedded within the engineered tissue (Figure 6D, right).

Example 5-Engineered Tissue Having A Vascular Stent Embedded Therein

[0038] Small diameter nitinol vascular stents (14 mm internal diameter (ID)) were embedded in engineered tissue by placing nitinol stent in a tubular plastic mold with channels for leaflets (Figure 7A). The mold was filled with gelation solution containing fibrinogen, thrombin and dermal fibroblast. Once the gel is formed, the embedded nitinol stent is cultured in cell culture media for 7 weeks. The final product is cell produced extracellular matrix containing a nitinol stent as luminal wall with leaflets (two) in the central lumen as shown in Figure 7B and 7C. The valve end-on images during open and close are shown in Figure 7D.

Example 6-Valve Performance Testing

[0039] Figure 8 shows the results of performance testing of the bi-leaflet tissue-engineered vein valve shown in Figure 7. The valve was evaluated for hemodynamics performance by mounting in a pulse duplicator (ViVitro System). Figure 8A shows the results from a failure test, in which the back-pressure of the engineered valve is comparable to a native ovine vein valve. Figure 8B shows the results from a dynamic flow test, showing cyclic flow and noflow phases as the pressure gradient reverses, and a systolic pressure gradient of only 1-2 mm Hg.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not

form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US2014180399A](#) [0004]
- [US6666886B](#) [0014]
- [US20140058496A](#) [0014]
- [WO2007025233A](#) [0019]
- [WO2010120539A](#) [0019]

Non-patent literature cited in the description

- **OTT et al.** Nat. Med., 2008, vol. 14, 213-21 [0019]
- **BAPTISTA et al.** Conf. Proc. IEEE Eng. Med. Biol. Soc., 2009, vol. 2009, 6526-9 [0019]
- **CRAPO et al.** Biomaterials, 2011, vol. 32, 3233-43 [0019]

Patentkrav

1. Fremgangsmåde til fremstilling af et modificeret decellulariseret væv der omfatter en del af en strukturel komponent, som er indlejret deri, hvilken fremgangsmåde omfatter:

5

at kombinere matrix-producerende celler med en hydrogel for at fremstille en celle-podet hydrogel, hvilken hydrogel omfatter fibrinogen og thrombin;

10

at danne den celle-podede hydrogel på, i, omkring og/eller inden for en del af den strukturelle komponent; og

15

at dyrke og decellularisere den celle-podede hydrogel under passende betingelser, således at der produceres et modificeret decellulariseret væv som omfatter en del af den strukturelle komponent, der er indlejret deri, hvor en del af den strukturelle komponent ikke er indlejret i det modificerede decellulariserede væv.

2. Fremgangsmåden ifølge krav 1, hvor de matrix-producerende celler er fibroblaster, glatte muskelceller eller interstitielle celler.

20

3. Fremgangsmåde ifølge et hvilket som helst af kravene 1-2, hvor den strukturelle komponent er en stent, en flig, et net eller en kappe, hvor den strukturelle komponent eventuelt består af metal eller legering, plast, keramik, stof eller en kombination deraf.

25

4. Fremgangsmåde ifølge et hvilket som helst af kravene 1-3 der yderligere omfatter mekanisk manipulation af hydrogelen i dyrkningstrinnet for at fremstille det modificerede decellulariserede væv.

30

5. Fremgangsmåde ifølge et hvilket som helst af kravene 1-4 der yderligere omfatter recellularisering eller kemisk-modificering af det modificerede decellulariserede væv.

6. Modificeret decellulariseret væv der omfatter en del af en strukturel komponent, som er indlejret deri, hvor en del af den strukturelle komponent ikke er indlejret i det modificerede decellulariserede væv, hvilket væv er opnået ved fremgangsmåden ifølge et hvilket som helst af kravene 1-5.

5

7. Modificeret decellulariseret væv ifølge krav 6, hvor den strukturelle komponent eventuelt er en stent, en flig, et net eller en kappe, hvor den strukturelle komponent eventuelt består af metal eller legering, plast, keramik, stof eller en kombination deraf.

10

8. Modificeret decellulariseret væv ifølge et hvilket som helst af kravene 6-7, hvor det modificerede decellulariserede væv er valgt fra gruppen, der består af: et vaskulært transplantat, en hjerteklap, en veneklap, et arteriovenøst transplantat, en urinleder, et urinrør, et spiserør, et luftrør, hud, sener og ledbånd, uterusrør (eksempelvis æggeleder) og broknet.

15

9. Modificeret decellulariseret væv ifølge krav 6,

hvor den strukturelle komponent omfatter en første ende og en anden ende, hvor den første ende omfatter en ventilstent, og den anden ende omfatter en rørformet struktur;

20

hvor den rørformede struktur af den strukturelle komponent er indlejret i det modificerede decellulariserede væv og

hvor ventilstenten ikke er indlejret i det modificerede decellulariserede væv.

25

10. Modificeret decellulariseret væv ifølge krav 9, hvor den rørformede struktur af den strukturelle komponent omfatter en ventilbladstråd.

30

11. Modificeret decellulariseret væv ifølge krav 9 eller 10 der omfatter en suturmanchet, som er fastgjort til den anden ende af den strukturelle komponent.

12. Modifieret decellulariseret væv ifølge krav 9-11, hvor den strukturelle komponent består af nitinol.

DRAWINGS




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4A




FIGURE 4B




FIGURE 5A

FIGURE 5B




FIGURE 6A





FIGURE 6B



Uncrimped stent extending
beyond the valve crimper

Valve crimped from
23 mm to 8 mm
diameter

FIGURE 6C




FIGURE 6D




FIGURE 7




FIGURE 7D




FIGURE 8